GBIO vs. GTHX, MACK, FHTX, IMMP, PRLD, ACRV, GALT, OVID, DSGN, and QURE
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include G1 Therapeutics (GTHX), Merrimack Pharmaceuticals (MACK), Foghorn Therapeutics (FHTX), Immutep (IMMP), Prelude Therapeutics (PRLD), Acrivon Therapeutics (ACRV), Galectin Therapeutics (GALT), Ovid Therapeutics (OVID), Design Therapeutics (DSGN), and uniQure (QURE). These companies are all part of the "pharmaceutical preparations" industry.
G1 Therapeutics (NASDAQ:GTHX) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
G1 Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.78, suggesting that its share price is 178% more volatile than the S&P 500.
Generation Bio has a net margin of 0.00% compared to Generation Bio's net margin of -58.13%. G1 Therapeutics' return on equity of -52.29% beat Generation Bio's return on equity.
G1 Therapeutics currently has a consensus target price of $9.33, suggesting a potential upside of 133.33%. Generation Bio has a consensus target price of $8.00, suggesting a potential upside of 175.86%. Given G1 Therapeutics' higher probable upside, analysts plainly believe Generation Bio is more favorable than G1 Therapeutics.
24.2% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 8.2% of G1 Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Generation Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, G1 Therapeutics and G1 Therapeutics both had 3 articles in the media. Generation Bio's average media sentiment score of 1.01 beat G1 Therapeutics' score of 0.01 indicating that G1 Therapeutics is being referred to more favorably in the media.
G1 Therapeutics has higher revenue and earnings than Generation Bio. G1 Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
G1 Therapeutics received 268 more outperform votes than Generation Bio when rated by MarketBeat users. However, 66.67% of users gave Generation Bio an outperform vote while only 65.66% of users gave G1 Therapeutics an outperform vote.
Summary
Generation Bio beats G1 Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
